---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-000858"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:39:24.945529+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Relmada Therapeutics CMO Cedric O'Gorman departs effective Jan 3, 2024

## Summary
- Dr. Cedric O'Gorman concluded his role as Chief Medical Officer on January 3, 2024, by mutual agreement.
- No successor or interim CMO has been announced by the company.
- CMO departure creates uncertainty for Relmada's clinical development programs.

## SEC filing metadata
- accession: 0001213900-24-000858
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390024000858/0001213900-24-000858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390024000858/ea191111-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-000858
- JSON: https://secwatch.observer/filing/0001213900-24-000858.json
- Plain text: https://secwatch.observer/filing/0001213900-24-000858.txt

## Key facts
- Executive change
  Cedric O’Gorman departed as Chief Medical Officer at RELMADA THERAPEUTICS, INC..
  - Action: concluded his service
  - Role: Chief Medical Officer
  source text: On January 3, 2024, Dr. Cedric O’Gorman concluded his service as Chief Medical Officer of Relmada Therapeutics, Inc. (the “Company”), as mutually agreed upon between him and the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390024000858/0001213900-24-000858-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.